Insights

2 highly rated blue chip ASX 200 shares

There are many blue chip options for investors on the ASX. Are these among the best?
The post 2 highly rated blue chip ASX 200 shares appeared first on The Motley Fool Australia. –

Given the large number of blue chip shares out there for investors to choose from, it can be hard to decide which ones to buy.

In order to narrow things down for you, I have picked out two blue chip shares which come highly rated right now. They are as follows:

CSL Limited (ASX: CSL)

The first blue chip share to look at is CSL. It is one of the world’s leading biotechnology companies with a portfolio of leading therapies and vaccines. This includes flu vaccines, immunoglobulins, and countless other plasma-based products.

However, the company isn’t settling for that and continues to invest heavily in its research and development (R&D). In fact, each year, the company invests somewhere in the region of 11% of its sales back into R&D activities. This means that approximately US$1 billion will be spent this year to ensure that the company’s R&D pipeline is filled to the brim with innovative and potentially lucrative products.

One leading broker that is positive on the company is Citi. Its analysts currently have a buy rating and $310.00 price target on its shares.

Sonic Healthcare Limited (ASX: SHL)

Another blue chip ASX 200 share to consider is Sonic Healthcare. It is a leading medical diagnostics company which has been growing at a very strong rate in FY 2021.

For example, during the first half, the company delivered a 33% increase in revenue to $4.4 billion and a 166% jump in first half net profit to $678 million. A key driver of this growth was strong demand for COVID-19 testing services, which was supported by positive performances from the rest of the business.

And with COVID-19 testing expected to remain strong for a little while to come, Sonic looks set to continue its growth in FY 2022. In addition to this, due to its strong balance sheet, the company has the optionality to boost its growth through earnings accretive acquisitions.

One broker that is particularly positive on the company is Credit Suisse. It has an outperform rating and $40.00 price target on the company’s shares.

The post 2 highly rated blue chip ASX 200 shares appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

2 ASX 200 blue chip shares named as buys

5 ASX shares that haunt fund managers

ASX 200 Weekly Wrap: ASX hits 7,300 points for the first time

2 excellent ASX dividend shares for income investors

Top brokers name 3 ASX shares to buy next week

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Important Notice
Trade The US Market With ZERO Brokerage* + FREE Access To Trading Ideas & Value Analysis Tools. Click Here!